Use Of Viral Il-6 To Modulate Monocyte Differentiation To Boost Anti-Tumor Immunity

Abstract

Researchers at the University of California, Davis have developed a virally derived homolog to increase the inflammatory response desirable in cancer immunotherapy.

Full Description

Researchers at the University of California Davis have developed the use of a virally derived homolog of interleukin-6 (vIL-6) to increase the inflammatory response desirable in cancer immunotherapy. The technology promotes dendritic cell differentiation and M1 macrophage differentiation from monocytes, unlike human IL-6, and doesn't trigger anti-inflammatory negative feedback mechanisms. The technology includes the RNA- and viral vector-based delivery of vIL-6-encoding nucleic acids.

Unlike IL-6, vIL-6 does not trigger negative feedback regulation, thus providing a unique benefit when it's used therapeutically as it does not limit its own efficacy by self-downregulation. This new technology aims to enhance cancer therapy by combining the administration of vIL-6 with an anti-cancer therapeutic agent, especially an anti-cancer immunotherapeutic agent.

Applications

• Development of new medication and treatments for cancer 
• Potential use in research and development in the medical and pharmaceutical industry 
• Useful in the field of cancer therapeutics, specifically in immunotherapy 
• Potential application in the manufacturing of cell culture mediums 
• May be incorporated into various delivery systems such as viral vector-based delivery, liposomal formulations, transdermal patches, etc for treating cancer

Features/Benefits

• Increases the inflammatory response desirable in cancer therapies 
• Promotes dendritic cell differentiation and M1 macrophage differentiation 
• Utilizes RNA- and viral vector-based delivery for effective implementation 
• Does not self-downregulate which is an issue with existing therapies that are limited by negative feedback mechanisms 
• Can be applied in various formats such as protein form or nucleic acid form 
• Potential supplement for cell culture to enhance the recovery and efficacy of dendritic cells

Patent Status

Patent Pending